(365 days)
The UM-L20/UML30 CO2 Laser Units are used in the following applications in order to treat the below mentioned conditions: ENT, Plastic & Reconstruction, Dermatology, Podiatry, Dentalogy, General Practice, Gynecology, Proctology. Specific conditions are listed in tables.
Not Found
I am sorry, but based on the provided document, I cannot answer your request. The document is a 510(k) clearance letter from the FDA for a CO2 laser device (UM-L20 and UM-L30). It establishes the substantial equivalence of the device to a legally marketed predicate device and lists its indications for use.
However, the document does not contain any information regarding:
- Acceptance criteria and reported device performance: There are no specific performance metrics, benchmarks, or data presented.
- Details of any study: The document doesn't describe any studies conducted to prove the device meets acceptance criteria. This includes no information on sample sizes, data provenance, ground truth establishment, expert qualifications, adjudication methods, MRMC studies, or standalone algorithm performance.
The FDA 510(k) clearance process primarily focuses on demonstrating substantial equivalence to a predicate device, rather than requiring extensive clinical trials with detailed performance reports as might be seen for devices needing PMA approval. Therefore, the information you are requesting is not typically included in these types of regulatory documents.
§ 878.4810 Laser surgical instrument for use in general and plastic surgery and in dermatology.
(a)
Identification. (1) A carbon dioxide laser for use in general surgery and in dermatology is a laser device intended to cut, destroy, or remove tissue by light energy emitted by carbon dioxide.(2) An argon laser for use in dermatology is a laser device intended to destroy or coagulate tissue by light energy emitted by argon.
(b)
Classification. (1) Class II.(2) Class I for special laser gas mixtures used as a lasing medium for this class of lasers. The devices subject to this paragraph (b)(2) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 878.9.